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Abstract
Our aim was to present a comprehensive, updated survey on obsessive-compulsive disorder
(OCD) and obsessive-compulsive related disorders (OCRDs) and their clinical management via
literature review, critical analysis and synthesis.
Information on OCD and OCRD current nosography, clinical phenomenology and etiology, may
lead to a better comprehension of their management. Clinicians should become familiar with the
broad spectrum of OCD disorders, since it is a pivotal issue in current clinical psychiatry.
Introduction
Obsessive-compulsive disorder (OCD) is a common,
chronic, anxiety condition that can have disabling effects
on both genders throughout the patient's lifespan. OCD
can manifest with a wide range of clinical pictures [1].
The disorder is among the most disabling anxiety condi-
tions and counts for more than half of serious anxiety
cases [2]. However, no univocal clinical opinion exists
about its classification. In fact, although the Diagnostic
and Statistical Manual of Mental Disorders, 4th edition –
text revision (DSM-IV-TR) [3] classifies OCD as an anxiety
disorder, some clinicians conceptualize it as a spectrum of
related disorders (OCRDs) sharing the 'anxiety/fear' cou-
pled with 'worry' clinical feature [4,5].
The broad spectrum of OCRDs includes the somatoform
disorders (for example, body dysmorphic disorder (BDD)
and hypochondriasis), the impulse-control disorders (for
example, trichotillomania (TTM), pathological gambling,
skin picking and others) and the tic disorders (for exam-
ple, Tourette's syndrome) but others, including drug-
induced and non-psychiatric disorders, could overlap and
show similar clinical pictures [6]. The National Comor-
bidity Survey Replication study reported more than a
quarter of evaluated subjects developing obsessions and
compulsions at some point in their life and possibly man-
ifesting with a full-threshold OCD, while a higher number
of patients will probably suffer from OCRDs [2].
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between 22 and 35, while affected patients spend an aver-
age of 17 years before receiving a correct diagnosis and
treatment, with most OCD and OCRDs often showing a
waxing and waning course, frequently increasing in sever-
ity when left untreated [7,8].
Further increasing the burden of OCD is the fact that
affected subjects, along with many psychiatric patients,
often experience discrimination and stigmatization due to
a non-medical perception of the phenomenon. Yet OCD
and OCRDs represent relevant medical conditions. Find-
ings provided by recent studies, mainly focusing on the
role played by the amygdala and its links to the 'fear cir-
cuits' and other structural and functional abnormalities of
several corticostriatal pathways, also indicate a relation-
ship between OCD manifestations and its neurobiologi-
cal basis, suggesting new therapeutic strategies [9].
Treatment of OCD typically involves the use of medica-
tions in combination with other modalities (such as cog-
nitive behavioural therapy (CBT), psychoeducation and
support groups and so on): first line treatments options
include both serotonin reuptake inhibitors (SRIs) medica-
tion and CBT [10], but anxiolitics and antipsychotics,
among other classes of drugs, are used as well. Finally, the
identification of OCD and its appropriate treatment is
essential to improve the quality of assistance and to
reduce the waste of health care resources through unnec-
essary medical care.
Historical background and current nosography
Obsessions thoughts and compulsive urges or actions are
part of everyday life. We return to check that we locked a
door and switched off the light. We cannot stop thinking
about the stressful event scheduled for the next week. We
refuse to eat with the spoon that dropped on the floor,
even if we know the chance of contamination is remote.
These events are part of the normal feedback and control
loop between our thoughts and our actions, and they have
an ancestral biological survival value. It is only when
obsessive thoughts become frequent or intense, or una-
voidable, or when these compulsive rituals become so
prominent that they interfere with an individual's func-
tioning, that the diagnosis of OCD is made.
Descriptions of the phenomena of obsessions and com-
pulsions can be found in historical documents over the
past several centuries, since OCD has a long history. A pas-
sage from the Malleus Maleficarum, the 15th century com-
pendium of witchcraft and psychopathology, describes a
priest brought to Rome for exorcism:
' [w]hen he passed any church, and genuflected in honour
of the Glorious virgin, the devil made him thrust his
tongue far out of his mouth when he tried to engage in
prayer, [the devil] attacked him more violently' [11].
Those with obsessive thoughts of a blasphemous or sexual
nature were thought to be partially possessed by the devil,
while 'psychotic' individuals appeared fully possessed.
Obsessions and hand-washing rituals resulting from guilt
were immortalized in the 17th century by the Shakespeare
character Lady Macbeth:
'[...] it is an accustomed action with her, to seem thus
washing her hands. I have known her continue with this a
quarter of an hour' (Macbeth, V.i.28, describing the time-
wasting characteristic of OCD).
With time, the explanation for obsessions and compul-
sions moved from a religious view to a medical one.
Obsessions and compulsions were first described in the
psychiatric literature by Esquirol in 1838, and, by the end
of the 19th century, they were generally regarded as man-
ifestations of melancholy or depression. By the beginning
of the 20th century, the view of obsessive-compulsive
phenomena had begun to shift OCD toward a psycholog-
ical explanation; Janet had already described the success-
ful treatment of compulsive rituals with what would come
to be known behavioral techniques [12], and with Freud's
publication in 1909 of the psychoanalysis of a case of
obsessional neurosis (the Rat Man), obsessive and com-
pulsive actions came to be seen as the results of uncon-
scious conflicts and the isolation of thoughts and actions
from their emotional components [13]. Although this
shift succeeded in pointing out that actions can be moti-
vated by factors of which the individual is unaware or
unable to control, it did little to improve the outcome of
patients OCD.
In the 1950s, with the rise of behavioral therapy, the
learning theories that had proved to be helpful in the con-
ceptualization and treatment of phobic disorders were
applied to OCD symptoms. Although these learning the-
ories are clearly insufficient to account for all OCD (as
well as OCRD) symptoms, they did lead to the develop-
ment in the late 1960s and early 1970s of effective treat-
ments for reducing compulsive rituals. During the 1980s,
research focused on the relationship of OCD and neuro-
logical problems such as epilepsy [14], memory disorders
and Tourette's syndrome [15] while Westphal's early
observation of an association between obsessions, tic dis-
orders and epilepsy already presaged recent neurobiologi-
cal findings in OCD.
OCD and OCRDs may also have common manifestations
and, since the 1990s, they have therefore been conceptu-Page 2 of 13
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(Figure 1) [17].
The 1994 DSM-IV operated a split between the phobic/
anxious-avoidant and obsessive dimensions, categorized
by the previous DSM-III (1980) and its 1987 revised edi-
tion (DSM-III-R) with the unitary diagnosis of 'phobic-
obsessive disorder' [18]. The current DSM-IV-TR describes
OCD as characterized by repetitive thoughts, images,
impulses that intrude on a patient unable to stop them
[3].
Current nosology underlines the following three major
symptom clusters for OCD and OCRDs: a 'somatic' cluster
for BDD and hypocondriasis, a 'reward deficiency' cluster
for TTM and other impulse control disorders (ICDs), and
an 'impulsivity' one for kleptomania, compulsive shop-
ping (CS), pathological gambling (PG), intermittent
explosive disorder (IED) and others [19].
While most psychiatrists generally agree on the OCD spec-
trum including anxious and phobic manifestations, a
greater number also focus on the need of a clear-cut defi-
nition of anxious and obsessive symptoms, as is antici-
pated by the research agenda for DSM-V[5]. In fact,
anxious phobia differs from OCD. Both phobic and
obsessive-compulsive subjects usually avoid feared
objects and generally retain awareness their fears and
avoidance behaviors are excessive. Phobics are usually
more upset about the prospect of actually coming into
contact with the thing they fear and do what they can to
avoid it, while OCD patients may be more concerned
about the time-consuming rituals such contacts will trig-
ger, rather than fear of the contact itself.
Epidemiology
Obsessive and compulsive symptoms are common and
not all of them may be accounted for a full-threshold
OCD. Approximately 50% of the general population
engage in some ritualized behaviors, while up to 80%
experience intrusive, unpleasant or unwanted thoughts
[20].
The 1 month prevalence of adult OCD is about 0.6% [21]
while the DSM-IV 12 month prevalence ranges from 0.6%
to 1%. Regardless, the prevalence of OCD, as well OCRDs,
may vary depending on the source of data and the choice
of diagnostic instruments. Many OCRDs may co-occur
with each other and with OCD. With regard to the
somatoform disorders, the estimated prevalence rate of
hypochondriasis is 1% to 5% in the general population
and 2% to 7% among primary care outpatients. Unfortu-
nately, the prevalence rate of BDD is difficult to estimate
given the secrecy of this severe condition [22], but esti-
mates range from 0.7% to 2.3% in the general population
and at least from 6% to 15% in cosmetic surgery settings
[23]. For OCRDs the prevalence of Tourette's is 0.1%,
while the exact lifetime prevalence of TTM is unknown,
but rates from 1% to 2% have been reported for cases that
satisfy the full threshold diagnostic criteria [24].
There seems to be a bimodal age of onset for OCD. The
mean onset has been reported to be 19 years (21% of the
cases emerged at age 10), while the mean age for adult
OCD occurs between age 22 and 35. In a small number of
cases the onset of the disorder occurs at age of 50 or more
[2]. Usually, the earlier the age of onset, the worse the
course of OCD and OCRDs; by contrast, no specific gen-
der predominance has been reported in large samples epi-
demiological studies. This latter evidence is in contrast
with non-OCD anxiety conditions whose gender ratios
usually indicate a prevalence of female cases [25].
While economic, social and cultural effects may play a
role in producing different clinical pictures of OCD, bio-
logical, immune and genetic factors and family predispo-
sition may also contribute to the pathogenesis of the
disorder. For example, streptococcal infection may be
associated with an abrupt, exacerbating-remitting early-
onset form of OCD, which is termed pediatric autoim-
mune disorder associated with streptococcus (PANDAS),
but little is known about this condition, and in particular
about the genesis of this OCRD [26].
OCD's burden may also vary depending on the case in
question, on the course of disorder and on the fact it is
almost unknown among the general population. As a con-
sequence, many patients do not seek medical care until
(originally) milder forms of OCD and OCRDs become
more distressful and possibly harder to treat. Further-
more, a large number of obsessive-compulsive conditions
may go under-diagnosed: studies have placed the preva-
lence between 1% and 3% of OCD cases, although the
prevalence of clinically recognized OCD is probably
much lower [2].
The fact that many individuals do not seek early appropri-
ate treatments may be due to stigma, but also to other fac-
tors. Sometimes patients do not realize that they are
affected by OCD. In some cases, the 'typically obsessive'
features of intrusive, 'ego-dystonic' feelings and thoughts
are absent, as in the poor-insight obsessive-compulsive
disorder (PI-OCD), complicating the course and severity
of the illness [27]. Including PI-OCD and other subtypes
extends the range of OCD cases that are reported to afflict
approximately 2% to 3% of the world's population; these
show varying degrees of severity and chronic course and
often also include depressive feelings (80%), major
depression (MD) comorbidity (30%) and Tourette's syn-
drome comorbidity (5%).Page 3 of 13
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The current spectrum of obsessive-compulsive disorder (OCD) and related disorders (OCRDs)Figure 1
The current spectrum of obsessive-compulsive disorder (OCD) and related disorders (OCRDs). Adapted from 
Roan WM et al. [17].
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Annals of General Psychiatry 2009, 8:13 http://www.annals-general-psychiatry.com/content/8/1/13Additionally, OCD patients usually present symptoms
similar to those of their affected relatives. About 8% of
first degree relatives have OCD, while first symptoms
occur by their 20s in 75% of the patients; this may happen
suddenly or slowly, generally showing an episodic course
[28]. Interestingly, the episodic course is sometimes an
overlap feature of the illness with MD, but it may also
prompt clinicians to explore other affective comorbidities
as well [29], and we urge for more vigilance for largely
under-recognized entities such as cyclothymic-OCD [30].
For example, a small number of very severe OCD cases
may also develop suicidal ideations or behaviors, as the
patient could be perceive suicide as the only possibility of
escape from their tremendous pain. In such patients, a
common neurobiological and genetic basis has been
hypothesized to be responsible for depressive suicidal
behaviors and for severe ego-dystonic obsessive manifes-
tations. Such a hypothesis has also been supported by the
ex adiuvantibus findings of similar pharmacotherapeutic
strategies being effective in both pathological dimensions.
Diagnostic criteria
The main features of OCD are the obsessions and compul-
sions. According to DSM-IV-TR, the obsessions and com-
pulsions cause marked distress, are time-consuming
(usually taking more than 1 h per day for a month or
more) and significantly impair the normal functioning of
the subject. If another Axis I disorder is present, it is man-
datory that the content of the obsessions or compulsions
not be restricted to it (for example, preoccupation with
food or weight in eating disorders or guilt ruminations in
the presence of a major depressive episode (MDE)). The
disturbance should not be due to the direct effects of a
substance (for example, drug or medication abuse), or a
general medical condition (Figure 2).
Obsessions may also manifest with very heterogeneous
clinical pictures (for example, religious scrupulosity,
aggressive or intrusive thoughts, inappropriate sexual
thoughts, concerns about symmetry and perfectionism,
pathological doubt, contamination worries, pathological
collecting and hoarding), while compulsions are defined
as repetitive behaviors or mental acts (for example, wash-
ing, counting, checking, ordering, touching, cleaning,
hoarding, conducting mental or physical rituals).
Obsessions are usually unwanted, unavoidable, intrusive,
ego-dystonic, occasionally frightening or violent (for
example, the impulse to leap before a car, the thought that
you may attack your spouse, that the pateint may molest
a child) and often impair functioning and quality of life
(QoL) [31].
It is remarkable that most OCD patients do criticize their
own thoughts and would hate to practice any by choice,
yet in most cases they are unable to stop such thoughts or
behaviors. Nevertheless, OCD patients can ruminate end-
lessly ('Did I lock the door?') and most of them develop
(new) compulsions to ward off unwanted happenings or
to satisfy obsessions (for example, an obsession with dirt
leading to hand-washing rituals).
Differential diagnosis and clinical 
phenomenology
The word 'obsession' derives from Latin 'obsidēre', which
means 'to take possession', 'to occupy'. In fact, most OCD
patients relate to the experience of a 'Middle ages fortress
besieged by strong enemies they have to surrender to
without any escape possibility'. The Latin word 'compellere'
has the significance of 'to be constrained' and 'to be over-
powered': OCD patients are forced to act on compulsions
trying to overcome obsessions.
Most OCD patients present both, but occasionally they
can manifest only obsessions or compulsions; this is suf-
ficient for OCD diagnosis regardless.
Up to 20% of severe depression cases present obsessive
symptoms and treatment maybe identical while schizo-
phrenics often show bizarre rituals they are usually com-
fortable with, as in schizo-obsessive disorder (SOD)
which neurological soft signs (NSS) psychopathology sug-
gests is a severe form of OCRD [32-34].
Differential diagnosis is also a concern due to current
OCD and OCRD classification methods. People some-
times wonder if compulsive eating, gambling, shopping
or deviant sexual behaviors are forms of OCRD. Usually,
these disorders are not classified as OCRDs because some
pleasure is obtained by these activities and the person
would not, ordinarily, wish to stop them except for the
secondary problems they may cause (such as obesity, con-
victions for driving while intoxicated, gambling and credit
card debts and criminal prosecution for sexual deviancy).
Nevertheless, few individuals with these compulsive
behaviors may respond to drug and behavioral treatments
that are effective for OCD [7].
Obsessions usually share an increasing 'anxious tension'
before acting the compulsions (both behavioral and men-
tal), followed by a brief sense of relief as they are carried
out. This kind of feeling is particularly evident in many
OCRDs too, as most eating disorders (EDs) may also be
considered. In fact, many bulimia nervosa (BN) patients
experience a brief reaction after binge eating while ano-
rexia nervosa (AN) patients take a form of pleasure in
being able to keep away from food.Page 5 of 13
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sive symptoms in the course of EDs and OCD symptoms;
a distinction should also be made for 'anxious' feelings
experienced in the course of ICDs when the compulsion is
carried out.
Occasionally OCD thinking is bizarre, and patients could
even exhibit schizotypical personality disorder (SPD)
traits, usually being unaware of this (for example, 'My
spouse will leave me if I do not catch the elevator').
Since the OCD spectrum phenomenology may be vary
heterogeneous, many rating scales and instruments, such
as the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
and others also investigating OCRDs, have been devel-
oped to help clinicians make diagnoses and to score
symptoms, but clinical interview by a trained psychiatrist
should not be discounted in any serious case [35].
Neurobiology and genetics
There is growing evidence based on several lines of
research that OCD and OCRDs involve abnormal metab-
olism in specific areas of the brain. Neuroimaging find-
ings indicate OCD involves subtle structural and
functional abnormalities of the orbito-frontal cortex
(OFC), the anterior cingulate cortex (ACC), the caudate
Diagnostic and Statistical Manual of Mental Disorders, 4th edition – text revision (DSM-IV-TR) criteria for obsessive-compul-sive disorder (OCD)Figure 2
Diagnostic and Statistical Manual of Mental Disorders, 4th edition – text revision (DSM-IV-TR) criteria for 
obsessive-compulsive disorder (OCD).
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nucleus (NAc), the cortical thalamic nuclei (Tn) as well
the white matter (WM), the hippocampus (HP) and other
regions [36].
The OFC is involved with social consciousness regarding
proper behavior. Hypoactivity in this area (whether occur-
ring spontaneously or as a result of damage from a perina-
tal or head injury, temporal lobe epilepsy, infection or
brain tumor and other conditions) leads to coarsening of
social consciousness and behaviors. This may lead to
hypersexuality (paraphilic OCRDs), overeating behavior
(EDs and Prader-Willi syndrome (PWS)), personality
changes and Tourette's syndrome (frequently presenting
with inappropriate use of profanity) or crude jokes (sado-
masochistic disorder (SMD)). Overactivity of the OFC
may results in excessive social concern, meticulousness
and 'nitpicking' habits, fastidiousness and avoidant
behaviors and more.
Other brain structures, such as the Cn, filter information
coming from the forebrain, representing a sort of hub for
many elaborate stimuli. It has been hypothesized that if
'too many' messages regarding worries about 'how things
should be done' reach the Cn, they are not filtered prop-
erly and spill over into (and flood) consciousness.
Increased metabolism of the frontal part of the brain is
concerned with order and social proprierty. The Cn, along
with other striatal structures, is also involved in regular
repetitive behaviors (rituals): the anterior caudatus puta-
men (aCPu), the ACC directly leading to the shell of the
NAc, the pallidus internus and the thalamus may play a
specific role in impulsive-repetitive psychic manifesta-
tions of OCD and OCRDs (for example, the verbal
Tourette's symptoms).
Additionally, the dysregulation of the posterior caudatus
putamen (pCPu) and the dorsolateral-prefrontal cortex
(DL-PFC), the pallidus internus (PI) and the thalamus
may account for the neurological symptoms such as tics,
Tourette's motor abnormalities and other OCD spectrum
motor issues [32].
Both the striatal and the frontal brain areas are richly sup-
plied with serotonergic neurons. It is not surprising that
most OCD and OCRD drugs act as modulators for the ser-
otonergic transmission in the central nervous system
(CNS). However, even though 5-hydroxytryptamine (5-
HT) is a core neurotransmitter involved in OCD and
OCRD manifestations, this knowledge tells us little about
the ultimate causes or triggers of this psychopathology or
about effective treatments.
5-HT abnormalities may be the result of rather than cause
of OCD and OCRD symptoms. Additionally, changes in
serotonergic transmission may have direct or indirect
effects on the neuronal firing of more than 60 other neu-
romodulators affecting thoughts, feelings and behaviors.
Thus, OCD is probably the final expression of many dif-
ferent kinds of abnormalities in the structure and func-
tioning of the brain. However, this complexity helps us to
understand why some treatments are helpful while others
are not as effective. The 5-HT hypothesis was initially
motivated by the observed differential efficacy of selective
SRIs (SSRIs) in alleviating OCD symptoms. These find-
ings, although attesting to the therapeutic versatility of
serotonin transporter inhibition in OCD, do not necessar-
ily reflect the existence of neurobiological abnormality in
the central serotonergic system in OCD; a reasoning
referred to as an ex juvantibus argument [37]. There is also
growing evidence from both preclinical and clinical stud-
ies that the dopamine (DA) system may be involved in the
pathogenesis of OCD [38]. Studies on knockout (KO)
mice for 5-HT2C receptor, already described as a model for
obesity, showed increased chewing on non-nutritive clay
with a distinct 'neat' pattern and a reduced habituation of
head dipping activity as compared to the wild type, with
the conclusion that the 5-HT2C receptor null mutant
mouse provides a putative model for compulsive behavior
[39]. Tsaltas et al. have described a model based on per-
sistence in the context of rewarded spatial alternation
[40]. Using this behavior model, they have shown that 5-
HT2C receptors are implicated in the mechanisms underly-
ing the 'compulsive' behavior in this animal model for
OCD. Acute administration of meta-chlorophenylpipera-
zine (mCPP), a non-selective 5-HT receptor agonist
mainly acting at the 5-HT2C receptors but with some affin-
ity also for the 5-HT1B, 5-HT1A and α2-adrenergic recep-
tors, increased 'compulsive' behavior [37]. The selective 5-
HT1B receptor agonist naratriptan was not effective in this
animal model, supporting the role of 5-HT2C receptors
underlying the effect of mCPP [40]. On the basis of elec-
trophysiological data, Joel and Doljansky suggested that
compulsive lever-pressing depends on a phasic decrease
in stimulation of D1 receptor [41]. In a pharmacological
animal model for OCD, in which rats are chronically
treated with the selective D2/D3 receptor agonist quin-
pirole (QNP), a ritual-like set of behavioral acts resem-
bling OCD checking behavior, has been observed [42].
This 'compulsive' behavior depends on QNP administra-
tion, because it rapidly returns to normal behavior when
QNP administration is discontinued [43]. Postmortem
analysis in these animals revealed increased DA tissue lev-
els in the NAc and right-PFC. The DL-PFC enables tempo-
ral information processing and holding relevant
information online [44]. It is believed to mediate working
memory and executive functions. The basal ganglia are
thought to project back to these cortical areas though the
medial dorsal and anterior nuclei of the thalamus [45].Page 7 of 13
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OCRD to show an inherited transmission. Some families
have at least four successive generations with clear OCD
cases [46]. Since family members could have 'learned'
these behaviors from other relatives, the presence of OCD
across generations alone is not sufficient to unequivocally
prove inheritance [47]. However, successive family mem-
bers often have different obsessions and compulsions,
suggesting that they have not 'learned' them. What
appears to be inherited is the capacity to respond to com-
mon life experiences with obsessions and compulsions.
There are also studies of inheritance involving identical
(homozygotic) and fraternal (heterozygotic) twins, which
also provide supportive evidence for an inherited compo-
nent in OCD and OCRDs [48].
Molecular genetics studies have begun to provide evi-
dence that specific genes may play a role in the manifesta-
tions of OCD. Segregation analysis has examined familiar
patterns of OCD transmission [49,50].
The genetic hypothesis suggests at least few major genes
implicated in OCD and OCRDs, thus they are considered
oligogenic disorders. Among others, the following regions
have been suggested as susceptibility loci: 1q, 6q, 9p, 19q,
7p and 15q. Specifically, the chromosome 11p15 has
been linked and associated with a supposed gender effect
in the OCD etiology [51]. Interestingly, deletions and
other abnormalities of human chromosome 15q11-q13
are associated with two developmental disorders, PWS
and Angelman syndrome (AS), which may also present
with psychiatric symptoms such as binging and other
ICD-related and OCRD-related manifestations [52,53].
Detailed analysis of the 15q11-q14 sequence corrected
errors and gaps in the public access sequence to fully
reveal large segmental duplications at breakpoints for
PWS, AS, and inv dup(15) syndromes, confirming the
tight correlations between those conditions [54].
Dhossche et al. suggested an association between autism,
PWS, AS, catatonia and GABA dysfunction, and this
appears to be particularly interesting considering the clin-
ical and partial phenomenic overlap between those condi-
tions, which indeed may appear with OCD and OCRD-
related symptoms too [55]. PWS may present with atypi-
cal psychotic features and motor dysfunctions character-
ized by ritualistic, stereotyped and compulsive behaviors,
which may be treated with GABA mimetic compounds
such as lorazepam, valproic acid and possibly topiramate
[56]. Many of the known genetically-based neurodevelop-
mental disorders are associated with distinctive behavior
phenotypes such as this; behavioral phenotypes have
been elucidated by clinical research, from distinctive pro-
file or social traits, or have emerged as prominent syndro-
mic features. Social phenotypic findings exist for fragile X
syndrome, Down syndrome and PWS, Smith-Magenis
syndrome, Turner syndrome, Williams syndrome and
velocardiofacial syndrome, all possibly associated with
autism [57].
OCD candidate genes have been studied based on their
function and also their position in the genome. Serot-
onin-related genes in OCD include those coding for the 5-
HT transporter (5-HTT) and receptors (5-HT2A, 5-HT2B, 5-
HT2C and 5-HT1B) as well the 5-HT enzyme tryptophan
hydroxylase [58].
DA-related genes supposed to be implicated in OCD
include DA transporter (DAT) genes and the D2, D3 and D4
receptors [59,60], as well as the catechol-O-methyltrans-
ferase (COMT) and monoamine oxidase A (MAO-A)
enzymes [61]. Glutamate-related genes (GRIK and
GRIN2B) and transporters (SLC1A1) have also been inves-
tigated in OCD along with the neurotrophic tyrosine
kinase type 3 (NTRK3) and other genes such as the white
matter genes OLIG2 and MOG [62].
However, given the complexity of OCD phenotype, it is
unlikely that a single candidate gene will have a major
impact on the disorder. Additionally, many individuals
suffering from OCD have no family members presenting
obsessive-compulsive symptoms.
Treatment and management
The past 20 years have seen the emergency and evaluation
of two major effective forms of treatment for OCD and
OCRDs: CBT and drug therapy. Additionally, many other
modalities, including physical treatments as electrocon-
vulsive therapy (ECT) and ablative neurosurgical proce-
dures have been proposed as well and should not bet
disregarded even today [63].
Drug treatment using medications with marked effect on
serotonergic neurotransmission has been shown to be
effective in decreasing both obsessions and compulsions,
while combining this pharmacological approach with
CBT has been reported as the most effective strategy for
most OCD and OCRDs cases [64].
Yet, regardless the adopted therapeutic strategy, results
vary depending on many factors including the age of
onset of the disorder, how long it has been left untreated,
the OCRD subtype and/or comorbidity, the patient's
insight and compliance and others [8]. Additionally, the
therapeutic strategy should be 'tailored' for each single
case.
CBT helps patients learn how to quell the discomfort aris-
ing from obsessions and how to reduce or eliminate com-Page 8 of 13
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prevention (ERP) and also cognitive therapy (CT).
Behavior therapy is not something done to a patient: it is
a structured set of techniques the patient learns to employ
whenever anxiety, discomfort, or dysfunction arise
because of obsessions or rituals. Basically, patients are
asked to find and face the things they fear ('exposure') and
then to refrain from carrying out compulsive rituals ('ritu-
als or response prevention'), but other techniques may be
employed as well [65]. Various degrees of success ratio for
CBT as OCD or OCRD monotherapy have been reported
depending on many factors: the source and method of the
study, the session frequency, the OCRD subtype and oth-
ers [10,66]. Also, CBT has been hypothesized to be associ-
ated with brain glucose metabolism improvements for
OCD patients [67].
Since the combination of CBT and SRI drugs seems to
achieve the best results in clinical settings, this has been
proposed as first-line approach in most of cases [64].
Effective SRI treatments for OCD include SSRIs and tricy-
clic antidepressants (TCAs), especially clomipramine, a
tertiary amine. Relatively weak serotonergic TCAs, such as
the predominantly norepinephrergic secondary amines,
do not tend to be as effective in OCD and OCRD treat-
ment [64]. SRIs also include the serotonergic-norepine-
phrergic reuptake inhibitors (SNRIs), the serotonin
antagonist-reuptake inhibitors (SARIs) and others, but
stronger evidence is needed to support their use as effec-
tive monotherapy for OCD and OCRDs or, as for the anti-
MAOs, relevant clinical side effects may discourage or
limit their use [68].
The decision to initiate treatment with SSRI alone, CBT
only or a combination, depends on individual patients
variables. Non-drug compliance, pregnancy, breastfeed-
ing, very young or very old or mild OCD patients may pre-
fer CBT alone. SSRI treatment should represent the
desirable approach in most of the drug-treated cases
because of the side effects associated with the TCA clomi-
pramine.
Clomipramine still represents an effective treatment for
severe OCD and OCRDs [69], but as the classification of
OCD and OCRDs changed with the past editions of DSM
so did the therapeutic approaches.
An ex adiuvantibus confirmation of partial phenomenic
overlap in OCD-related clinical manifestations is histori-
cally provided by clomipramine's effectiveness in treating
such conditions, also leading researchers focusing on ser-
otonergic mechanism [70]. The pharmacological finding
that serotonergic agents are more effective for obsessions
and compulsions rather than non-serotonergic antide-
pressants, and that their anti-obsessive benefit it is inde-
pendent of the antidepressant action, also contributed to
the separation of OCD from mood disorders [71].
When considering the SSRI class, the choice of a specific
drug depends on evidence-based medicine but also on the
pharmacokinetic and pharmacodynamic properties of the
biologically active agent. To mention few, a long-half life
(T1/2) should be preferred for very anxious patients,
reducing the risk of rebound syndrome (RS) and allowing
fewer daily administrations, but it may be not suitable for
older patients. Likewise, pharmacodynamic aspects
should suggest anticholinergic (anti-Ach), anti-hys-
taminic type-1 (Anti-H1) and/or anti-alpha norepinephr-
ergic type-1 (anti-α1) side effects to be preferred when a
higher sedation is sought (for example, for very severe
ICDs, Tourette's and other OCRDs), while the mild pro-
DA agonistic action of others (such as the weak one pro-
vided by high-dosage sertraline) should be considered for
BDD, binging, craving and other OCRD-related pleasure-
seeking behaviors.
Indeed the SSRIs are an almost 5-HT 'selective' class of
drugs: weak pharmacodynamic actions could represent a
powerful clinical tool when properly managed.
Because many OCD patients respond to treatment with
SRIs, usually requiring and tolerating higher doses com-
pared to affective patients, OCD is often deemed a sero-
tonergic dysfunctional disorder. However, despite the
'selective' efficacy of (S)SRIs, many OCD and OCRD
patients fail to respond ('non-responders') to adequate
doses and time exposures (for example, 20 to 60 mg/day
of paroxetine for 12 weeks or 150 to 300 mg/day of clo-
mipramine for 12 weeks), or may require augmentation
strategies, usually performed by employing different
classes of drugs [64,72]. Additionally, higher doses and
the delay in the onset of action can be accounted for by
the greater delay in downregulation of serotonergic 5-
HT1B receptor in the OFC and the subsequent stimulation
of 5-HT2A receptor antagonists (such as atypical antipsy-
chotics (AA) also known as 5-HT2A>D2 receptor antago-
nists) can hasten or augment the effects of SRIs [73].
Consequently, the clinical management of resistant OCD
and OCRDs may first consider a hyperdose of SRIs, espe-
cially for hard-to-treat forms of OCRD (for example,
hoarder-collector patients), prior to augmentation strate-
gies [74]. The augmentation of SSRIs with clomipramine
showed significant improvements in Y-BOCS scores com-
pared to SSRI monotherapy, but pharmacokinetic interac-
tions and higher risk for serotonergic malignant
syndrome (SMS) may discourage this kind of procedure
[75]. Also, SRI anti-obsessive drugs have occasionally
been reported to be associated with birth defects, and theyPage 9 of 13
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Drug management of obsessive-compulsive disorder (OCD) and related disorder (OCRD) non-respondersFigure 3
Drug management of obsessive-compulsive disorder (OCD) and related disorder (OCRD) non-responders.
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Annals of General Psychiatry 2009, 8:13 http://www.annals-general-psychiatry.com/content/8/1/13should therefore be avoided in pregnant or breastfeeding
women (while young or old patients may require lower
doses).
Alternative augmentations for resistant OCD and OCRD
cases may include the use of low doses of dopaminergic
antagonists (haloperidol and pimozide or other typical
antipsychotics (TA) or the AA class), especially for poor-
insight patients (when compliant). AA may also contrib-
ute to mood stabilization in drug-induced manic patients
or true bipolars [76]. Also, AAs are less likely to cause
extrapyramidal symptoms (EPS) or neuroleptic malignant
syndrome (NMS) in sensitive subjects.
The efficacy of adjunctive TAs or AAs to SRIs in refractory
OCD may be due to direct dopaminergic D2 blockade sep-
arate (TA) or together (AA) with 5-HT2 receptor antago-
nism. Additionally, SRI-refractory OCD and OCRDs
patients may have additional dysfunctional abnormalities
in dopaminergic pathways that may require augmenta-
tion with DA-blocking drugs.
Recent neuroimaging findings have also proposed rilu-
zole and other glutamatergic modulators as a possible SRI
augmentation strategy for OCD-refractory patients, but
further evidence is needed [77-81]. The antiepileptic
mood stabilizers such as carbamazepine, topiramate,
gabapentin and others, due to the neuroinhibitorial CNS
action of GABA in OCD circuits, norepinephrergic α2 (for
example, clonidine) and β1 blockers (for example, propa-
nolol), selective 5-HT1A partial agonists (buspirone), clon-
azepam and other benzodiazepines (BDZ), opioid agents
(for example, tramadol), antiandrogens and adrenal ster-
oids (for example, flutamide), peptides (for example, oxy-
tocin), hallucinogenetic agents (for example, lysergic acid
diethylamide (LDS) and other drugs also acting as 5-HT2A
partial antagonists), inositol and more, have been pro-
posed, but no univocal opinion on their efficacy for non-
responder OCD and OCRDs patients exists (Figure 3).
While a high number of drugs is available for rational
OCD therapy, less literature evidence exists about OCRD
non-responders management, possibly due to a lower
prevalence and clinical recognition of this group; this is
why a good pharmacological background should never be
missed by the prescriber.
The concept of non-responders also implies a mismatch
between a diagnostic classification and treatment, and
this may prompt researchers and clinicians to revise cur-
rent nosography and biological hypothesis [5,82].
Conclusion
A better understanding of the clinical phenomenology,
etiology and therapy of obsessive-compulsive-spectrum
disorders will provide clinicians with important informa-
tion about the effective management of these conditions.
Most OCDs and OCRDs may go underdiagnosed or may
be not promptly treated. As a consequence, many patients
and their families may suffer unduly, while a delayed ther-
apeutic intervention may mean they do not recover as
effectively as an early dagnosis would allow.
Specifically, we suggest the following:
1. An early recognition of OCD and OCRDs will improve
outcome and reduce burden.
2. Following current diagnostic criteria may be a useful
approach in most cases, but a knowledge of OCD and
OCRD phenomenology is a unique opportunity to better
address the patient's needs. It also may lead to better com-
pliance between the caregiver and the patient through a
deeper understanding of each other goals.
3. To date, no univocal opinion exists about the neurobio-
logical basis of OCD spectrum disorders. Regardless, it is
important to know current literature evidence, as this is a
core mechanism to proposing a rational therapeutic strat-
egy.
4. Spreading knowledge of OCD and OCRD phenomena
may also lead to overcoming the stigma it is associated
with, and may finally lead to a greater comprehension of
such disorders.
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